A5032600714- Attention Deficit Hyperactivity Disorder
- Cancer Immunotherapy and Biomarkers
- Diabetes Management and Research
- Neuroendocrine Tumor Research Advances
- Renal Transplantation Outcomes and Treatments
- Pancreatic function and diabetes
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Bipolar Disorder and Treatment
- Autism Spectrum Disorder Research
- Genetics and Neurodevelopmental Disorders
- Children's Physical and Motor Development
- Diabetes Treatment and Management
- Bladder and Urothelial Cancer Treatments
- Functional Brain Connectivity Studies
- Virology and Viral Diseases
- Pancreatic and Hepatic Oncology Research
- Biomedical Ethics and Regulation
Western University
2019-2025
Children's Hospital of Western Ontario
2018
Victoria Hospital
2018
Child and Family Research Institute
2016
The treatment landscape of genitourinary cancers has significantly evolved over the past few years. Renal cell carcinoma, bladder cancer, and prostate cancer are most common malignancies. Recent advancements have produced new targeted therapies, particularly antibody–drug conjugates (ADCs), due to a better understanding underlying oncogenic factors molecular mechanisms involved. ADCs function as ‘drug delivery into tumor’ system. They composed an antigen-directed antibody linked cytotoxic...
We present a case of 60-year-old male diagnosed with metastatic clear cell renal carcinoma who developed hypoglycemia during induction ipilimumab and nivolumab treatment. This was as presumed type 1 diabetes mellitus secondary to immunotherapy.
<h3>Background</h3> Metastatic renal cell carcinoma (mRCC) is treated with dual immune checkpoint inhibitors (ICI) or ICI a VEGF-TKI. Despite improved outcomes, some patients do not benefit from the treatment due to disease resistance serious adverse events. We hypothesized that re-establishing healthy microbiome in mRCC before and during based combination therapy via transplantation does increase toxicity improves clinical response. The PERFORM trial (NCT04163289) single-arm phase I study...
Diabetes Mellitus is an uncommon but well-known immune-related adverse event.However, it typically characterized by initial hyperglycemia.We report a case of 60-year-old male diagnosed with metastatic clear cell renal carcinoma who developed type 1 diabetes mellitus secondary to immunotherapy first presentation hypoglycemia.